A new machine learning model using routine blood tests predicts treatment failure in autoimmune hepatitis patients with ...

Vir Biotechnology (NASDAQ:VIR) said its combination treatment for chronic hepatitis delta met the primary and key secondary ...

As the opioid epidemic has worsened in the United States, prevalence of hepatitis C has also increased. Hepatitis C is a bloodborne virus that damages the liver. It is mainly spread through sharing ...

Vir stock catapulted to a nearly two-year high Monday on a "clean win" for its experimental hepatitis D treatment.

With highest dose of siRNA therapy, 19% achieved a functional cure 24 weeks after treatmen ...

Shares of Vir Biotechnology rose after the company reported positive results from two studies for a chronic hepatitis treatment. The stock gained 16% to $14.19 in premarket trading on Monday. At ...

In this Healio video from the ACG Annual Meeting, Tatyana Kushner, MD, MSCE, discusses new treatments for hepatitis B and ...

For a decade now, the world has had highly effective medications for hepatitis C infections. In the United States, they’ve mostly been sitting on the shelf, according to a new study. These drugs, ...

Antiviral treatments play a crucial role in the survival of patients with either hepatitis B or C and liver cancer, but researchers have found that antiviral therapy is “severely underutilized” even ...

A study in Frontiers in Cellular and Infection Microbiology reveals distinct plasma proteomic trajectories for PD-1 blockade ...

Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) licensed from Alnylam ...

People with alcohol-associated hepatitis are more likely to die from the disease if they use cannabis. A large multinational ...